NewAmsterdam Pharma (NAMS) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for its cholesterol treatments Ubeslo and Evlarco.
The recommendation was based on phase 3 trial data showing LDL cholesterol reductions of up to 40% with Ubeslo and about 50% with the obicetrapib-ezetimibe combination Evlarco.
The European Commission will review the CHMP opinion and is expected to issue a final decision in the second half of 2026, NewAmsterdam Pharma said.
Shares of NewAmsterdam were up nearly 1% in Friday trading.
Price: $30.81, Change: $+0.26, Percent Change: +0.85%